NCT02790515
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Bone Marrow Diseases, +32 more
- Locations
-
- St. Jude Children's Research Hospital Memphis, Tennessee, United States
Clinical trial condition
Lymphoma
Explore clinical trials studying Lymphoma. Study availability and eligibility vary by location and protocol.
3,644 public trials
847 recruiting studies
Lymphoma trial results
Active, Not Recruiting
A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02734771
- Conditions
- Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, New York, United States
- University of Virginia Cancer Center Charlottesville, Virginia, United States
Active, Not Recruiting
Health Surveillance at University of Applied Science Hamburg (HAW)
NCT07089914
- Conditions
- Anxiety, Anxiety Acute, Anxiety Depression, +24 more
- Locations
-
- Hamburg University of Applied Sciences/Hochschule für Angewandte Wissenschaften Hamburg (HAW Hamburg) Hamburg, Germany
Active, Not Recruiting
Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma.
NCT07101913
- Conditions
- Acute Kidney Injury, Acute Kidney Injury (AKI), B Cell Lymphoma, +18 more
- Locations
-
- Nephrology department, Centre hospitalier Lyon Sud Pierre-Bénite, France
Active, Not Recruiting
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
NCT02911142
- Conditions
- B-Cell Neoplasm, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
Active, Not Recruiting
Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies
NCT06220097
- Conditions
- B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory, Burkitt Lymphoma, +16 more
- Locations
-
- Union Hospital, Huazhong University of Science and Technology Wuhan, Hubei, China
Active, Not Recruiting
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
NCT03843294
- Conditions
- Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Hodgkin Disease, +11 more
- Locations
-
- Utah University School of Medicine/Huntsman Cancer Institute Salt Lake City, Utah, United States
Active, Not Recruiting
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
NCT04732845
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Disease, Chronic Lymphocytic Leukemia, +19 more
- Locations
-
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
Active, Not Recruiting
A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients With Grade 3A High-risk Follicular Lymphoma
NCT06742879
- Conditions
- Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- the First Affiliated Hospital of zhengzhou University Zhengzhou, Henan, China
Active, Not Recruiting
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT06601504
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Fujian Medical University Union Hospital Fuzhou, Fujian, China
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
- Guangxi Medical University Cancer Hospital Nanning, Guangxi, China
- Wuhan Union Hospital of China Wuhan, Hebei, China